NASDAQ : PACB
Pacific Biosciences of California, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 2.455 USD (Oct 30, 2026, 2:42 PM EDT) · Market cap 763.09M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 809.71M |
| Enterprise Value | 1.28B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 310.83M |
| Shares Outstanding | 310.83M |
| Shares Change (YoY) | +5.75% |
| Shares Change (QoQ) | +1.58% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 59.24% |
| Float | 304.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.08 |
| Forward PS | 4.76 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.05 |
| EV / EBITDA | 6.44 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.92 |
| Quick Ratio | 3.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | 3.39 |
| Debt / FCF | n/a |
| Interest Coverage | -24.22 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -929.32% |
| Return on Assets (ROA) | -14.07% |
| Return on Invested Capital (ROIC) | -15.42% |
| Return on Capital Employed (ROCE) | -25.99% |
| Weighted Average Cost of Capital (WACC) | 9.08% |
| Revenue Per Employee | $328,394 |
| Profits Per Employee | -$270,901 |
| Employee Count | 485 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 1.96 |
Taxes
| Measure | Value |
|---|
| Income Tax | 827,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +29.60% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 1.61 |
| Relative Strength Index (RSI) | 61.24 |
| Average Volume (20 Days) | 16,055,873 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 46.93M |
| Short Previous Month | 47.22M |
| Short % of Shares Out | 15.10% |
| Short % of Float | 15.43% |
| Short Ratio (days to cover) | 2.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 159.27M |
| Gross Profit | 46.86M |
| Operating Income | -177.54M |
| Pretax Income | -130.56M |
| Net Income | -131.39M |
| EBITDA | 199.18M |
| EBIT | -177.54M |
| Loss Per Share | -$0.43 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 236.87M |
| Total Debt | 709.13M |
| Net Cash | -472.25M |
| Net Cash Per Share | -$1.52 |
| Equity (Book Value) | -33.21M |
| Book Value Per Share | -0.11 |
| Working Capital | 269.83M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -118.05M |
| Capital Expenditures | -5.37M |
| Depreciation & Amortization | 376.71M |
| Net Borrowing | n/a |
| Free Cash Flow | -123.42M |
| FCF Per Share | -$0.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | 29.42% |
| Operating Margin | -111.47% |
| Pretax Margin | -81.97% |
| Profit Margin | -82.49% |
| EBITDA Margin | 125.05% |
| EBIT Margin | -111.47% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.75% |
| Shareholder Yield | -5.75% |
| Earnings Yield | -16.55% |
| FCF Yield | -15.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $2.54 |
| Price Target Difference | -2.38% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 9.66% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.88 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |